Taken together, these data highlight the need for careful methodological distinctions between lipofuscin autofluorescence, Aβ immunoreactivity, and APP-derived fragments, while supporting the broader concept that lipofuscin release into the extracellular space may play an underappreciated role in seeding or amplifying amyloid pathology in AD. This evidence concerns the gene APP and Alzheimer disease.